Albuterol Versus Xopenex in Treatment of Acute Asthma in the Emergency Department (ED) (Xopenex)

This study has been completed.
Information provided by:
Phoenix Children's Hospital Identifier:
First received: December 20, 2007
Last updated: September 2, 2011
Last verified: September 2011
The purpose of this study is to determine in a large, double-blind, randomized, prospective pediatric clinical trial whether the use of continuous levalbuterol (Xopenex) in addition to standard emergency department treatment for acute asthma exacerbations will improve the Forced Expiratory Volume in 1 sec (FEV 1) compared to the use of continuous racemic albuterol. The secondary objective is to correlate clinical (hospitalization rates and clinical asthma scores) with plasma levels of (S)-albuterol.

Condition Intervention Phase
Drug: xopenex
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Comparison of Hospital Admission Rates and Plasma(s)-Albuterol Levels in Children Treated With Racemic Albuterol Versus Levalbuterol for Acute Asthma Exacerbations: A Randomized Double-Blind Clinical Trial

Resource links provided by NLM:

Further study details as provided by Phoenix Children's Hospital:

Primary Outcome Measures:
  • Change in Forced Expiratory Volume in 1 Sec (FEV1) Measured in L/Sec [ Time Frame: Baseline and 4 hours ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Clinical Asthma Score (CAS) [ Time Frame: 4 hours ] [ Designated as safety issue: No ]
    Change in clinical asthma score while in ED. 15 point clinical asthma score. Score ranges from 5 (no to mild respiratory distress) to a maximum of 15 (severe respiratory distress).

Enrollment: 101
Study Start Date: September 2005
Study Completion Date: March 2009
Primary Completion Date: March 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A
levalbuterol nebulization
Drug: xopenex
will receive xopenex rather than albuterol to treat acute exacerbation
Other Name: levalbuterol

  Show Detailed Description


Ages Eligible for Study:   6 Years to 17 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patient is between the ages of 6 and 17
  • Has previously been diagnosed with asthma by any physician
  • Has presented to the ED with an asthma exacerbation judged by a physician to be of a moderate or severe degree

Exclusion Criteria:

  • Requires immediate resuscitation (attending physician)
  • Is pregnant and/or breast feeding
  • If possibly pregnant, negative pregnancy test attached
  • Has chronic lung diseases (i.e. cystic fibrosis)
  • Has an uncorrected congenital heart diseaseHas a suspected foreign body aspiration
  • Is allergic to albuterol and/or levalbuterol (Xopenex)
  • Has an initial FEV 1>70% predicted
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00585039

United States, Arizona
Phoenix Children's Hospital
Phoenix, Arizona, United States, 85016
Sponsors and Collaborators
Phoenix Children's Hospital
Principal Investigator: Robert Bulloch, MD Phoenix Children's Hospital
  More Information

Responsible Party: Robert Bulloch, MD, Phoenix Children's Hospital Identifier: NCT00585039     History of Changes
Other Study ID Numbers: SRC176 
Study First Received: December 20, 2007
Results First Received: March 17, 2011
Last Updated: September 2, 2011
Health Authority: United States: Institutional Review Board

Keywords provided by Phoenix Children's Hospital:
emergency department

Additional relevant MeSH terms:
Bronchial Diseases
Hypersensitivity, Immediate
Immune System Diseases
Lung Diseases
Lung Diseases, Obstructive
Respiratory Hypersensitivity
Respiratory Tract Diseases
Adrenergic Agents
Adrenergic Agonists
Adrenergic beta-2 Receptor Agonists
Adrenergic beta-Agonists
Anti-Asthmatic Agents
Autonomic Agents
Bronchodilator Agents
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Reproductive Control Agents
Respiratory System Agents
Tocolytic Agents processed this record on May 26, 2016